GM-CSF With Post-Transplant Cyclophosphamide

Launched by NORTHSIDE HOSPITAL, INC. · Jan 17, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients who are receiving a type of stem cell transplant for blood-related cancers, such as leukemia or lymphoma. The researchers want to see if using a medication called GM-CSF after the transplant can help patients recover their blood cell counts just as well as a commonly used treatment called G-CSF. Additionally, they hope that GM-CSF might lower the risk of infections that can occur after the transplant.

To participate in the trial, patients need to have a stem cell donor who is a partial match and should be in reasonably good health, as indicated by a performance status score of 70% or higher. This means they should be able to carry out daily activities with some assistance. However, individuals with serious heart, lung, liver, or kidney issues, those who are HIV-positive, or have a history of severe allergic reactions to GM-CSF should not participate. Participants in the study can expect close monitoring and support throughout the process, helping researchers understand how well this treatment works in comparison to traditional methods.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Availability of 5/10 to 8/10 matched related donor
• • KPS \>/= 70%
• • CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center
• Exclusion Criteria:
• • Poor cardiac, pulmonary, liver, and renal function
• • HIV-positive
• • Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent
• • History of severe or serious allergic reaction to human GM-CSF or yeast-derived products